

# California Department of Public Health


## Immunization Updates for Providers

Friday, January 19, 2024

9:00AM – 10:30AM

# Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, "Chat"



# Housekeeping

## Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

## Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#)



To be added to the CDPH email messaging listserv for providers, please email your request to [billiedawn.greenblatt@cdph.ca.gov](mailto:billiedawn.greenblatt@cdph.ca.gov)

If you have post-webinar-related questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov)

# Agenda: Friday, January 19, 2024

No.	Item	Speaker(s)	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	COVID-19 Vaccine Administration Data	Celeste Romano (CDPH)	9:05 – 9:10
3	Clinical Updates	Caterina Liu, MD (CDPH)	9:10 – 9:20
4	Therapeutics Billing Update	Edward Salaguinto, PharmD, RPh (CDPH)	9:20 – 9:30
5	Vaccines for Children (VFC)	Claudia Aguiluz (CDPH)	9:30 – 9:40
6	Vaccine Management	Josh Pocus (My Turn), Claudia Aguiluz (myCAvax), and Hannah Shows (Demo)	9:40 – 9:50
7	Resources and Q&A	Leslie Amani (CDPH)	9:50 – 10:30
<b>Thank you, providers of California!</b>			

# Announcements

Leslie Amani, CDPH

### About the Training Series:

- **What:** Building Impact: Your HPI Toolkit Training Series (6 sessions). Scroll down below and see attached flyer for details on each session.
- **When:** Sessions run January 2024 to June 2024, with each session scheduled for 60 to 90 minutes.
- **Where:** Virtual - Zoom. Register using the links down below.

## INTRO TO BUILDING IMPACT: YOUR HPI TOOLKIT

→ [Register for January 23, 2024, 1:00 to 2:00 PM](#)

Uncover the power of the NEW California Healthy Places Index® 3.0 in our introductory session. Get oriented to our training series and learn how HPI is used to impact community health across the state.

If you have any questions about this training series, please contact Helen Dowling at [hdowling@phi.org](mailto:hdowling@phi.org).

### Building Impact: Your HPI Toolkit

Unlock the full potential of the California Healthy Places Index® (HPI) in this comprehensive training journey for all skill levels.



You're invited to our *Building Impact* HPI training series – a dynamic learning journey designed for all audiences, whether you're a program specialist or a research scientist. Each session, scheduled from January to June, promises a hands-on experience with engaging activities, open discussions, and dedicated Q&A sessions.

With a practical focus and clear use cases tailored to your work, **feel free to register for one or join us for the entire series**, where each session builds upon the last, introducing

new skills and concepts to empower you in positively impacting community health across the state.

#### 1. INTRO TO BUILDING IMPACT: YOUR HPI TOOLKIT

[Register for January 23rd 1:00 – 2:00 PM](#)

Uncover the power of the NEW California Healthy Places Index® 3.0 in our introductory session. Get oriented to our training series and learn how HPI is used to impact community health across the state.

#### 2. HPI 101: A COMPASS FOR NAVIGATING PRIORITY COMMUNITIES

[Register for February 8th 1:00 – 2:30 PM](#)

Dive into the essentials of HPI, exploring its core principles and NEW data. Learn how to identify and characterize priority communities and equip yourself with the skills to accurately interpret HPI data.

#### 3. EQUITY OPPORTUNITIES UNVEILED: INFORMING PROGRAM DESIGN WITH HPI

[Register for March 7th 1:00 – 2:30 PM](#)

Discover opportunities to advance health equity as we explore how HPI can inform program design. Learn practical ways to leverage HPI data in shaping interventions that truly address the needs of diverse communities.

#### 4. ENGAGE, EMPOWER, ENRICH: STORYTELLING WITH HPI

[Register for April 11th 1:00 – 2:30 PM](#)

Embark on a journey of engagement strategies with HPI. Leverage the power of storytelling with HPI data to amplify community voices and foster connections that drive positive health outcomes.

#### 5. YOUR DATA & HPI

[Register for May 9th 1:00 – 2:30 PM](#)

Navigate the ins and outs of HPI data management in this session, including uploading your data to the HPI map and downloading HPI data through our API. Learn best practices to get the most out of using your data with HPI.

#### 6. HEALTH EQUITY METRICS & RESEARCH APPLICATIONS WITH HPI

[Register for June 4th 1 – 2:30 PM](#)

Explore the intersection of health equity metrics and research applications with HPI. Gain valuable insights into utilizing HPI data for impactful research that contributes to the broader goal of creating healthier and more equitable communities.



# Project ECHO\* Webinar

**Topic:** Respiratory Viruses in Older Californians: Epidemiology Update

**When:** Wednesday, January 24, 2024

**Time:** 12PM – 1PM, PT

**Registration Information:** [Project ECHO Home](#)



## Program Overview

The California Department of Public Health has requested that Family Health Centers of San Diego (FHCS) in collaboration with the UNM ECHO Institute implement a rapid, 3-4 month long biweekly mini-ECHO series focused on the prevention, diagnosis, and management of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus (RSV) and their respective complications specifically addressing the needs of the Skilled Nursing Facility context and programs focused on older adults. FHCS and UNM ECHO have previously collaborated on a similar 'COVID-19 Test to Treat' initiative directed at clinicians throughout California. The current SNF-targeted program is envisioned as a biweekly interactive webinar ECHO-like platform to engage on clinical issues related to COVID in nursing facilities.

## Target Audience

We will be targeting clinicians and administrators from Skilled Nursing Facilities, PACE programs, and other older adult-facing programs throughout California.





# California Primary Care Association Webinar

**Topic:** Immunization Recommendations During Pregnancy

**When:** Thursday, January 25, 2024

**Time:** 12PM – 1PM, PT

**Cost:** This webinar is sponsored by the CDPH Adult Immunization grant.

**Registration Instructions:** [CPCA Webinar Registration Link](#)

Presenters will review recommended immunizations during pregnancy, including newer RSV vaccines, and best practices for implementing and promoting prenatal immunizations. Participants will also learn, from a health center presenter, practical strategies for immunizing pregnant patients.

## **Presenters:**

- Tarek Salih, MD, MPH, MA, Public Health Medical Office, Immunization Branch, CDPH
- Arlene Pena, Senior Program Manager, Quality Improvement, Aliados Health
- Elizabeth Shaw, MD, Family Medicine, Medical Director of Quality Assurance & Improvement, Marin Community Clinics





# Look Ahead: Training Opportunities for VFA Providers

**Audience:** Identified Vaccines for Adults (VFA) key practice staff

## **Two Training Opportunities:**

Thursday, February 22, 2024, 11AM, PST: [VFA 101 Training for Providers](#)

Thursday, February 29, 2024, 11AM, PST: [VFA 102 Training for Providers](#)





# Vaccines for Adults (VFA) Resources

# CDPH Provider Webinars and Trainings

## Week of January 22, 2024

	Monday 1/22	Tuesday 1/23	Wednesday 1/24	Thursday 1/25	Friday 1/26
Live Webinars and Training		<p><b><i>New Training Series!</i></b></p> <p><a href="#">Building Impact: Your HPI Toolkit Training Series - Session 1 of 6: Introduction</a> 1:00 pm – 2:00 pm</p>	<p><a href="#">Project Echo Respiratory Viruses in Older Californians Webinar: Research and Epidemiology Update</a> 12:00 pm – 1:00 pm</p>	<p><a href="#">CPCA Webinar: Immunization Recommendations During Pregnancy</a> 12:00 pm – 1:00 pm</p>	<p><a href="#">CDPH Immunization Updates for Providers</a> 9:00 am – 10:30 am</p>
View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Weekly Provider Archived Webinars and Slides</a></li> <li><a href="#">COVID-19 Crucial Conversations Archived Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>	<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding (v. 1/4/22)</a></li> <li><a href="#">Latest Features in My Turn (Requires myCAvax Login)</a></li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)</a></li> </ul>	<ul style="list-style-type: none"> <li><a href="#">Moderna COVID-19 Vaccine Resources for Providers</a></li> <li><a href="#">CDC COVID-19 Vaccination Clinical &amp; Professional Resources</a></li> <li><a href="#">Novavax COVID-19 Vaccine Information</a></li> <li><a href="#">Pfizer COVID-19 Vaccine (COMIRNATY) Information</a></li> </ul>		

Help	<b>Help Desk</b>
	<p>*CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a>  My Turn: Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a>  myCAvax: Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a> Mpox: Email: <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a>  COVID-19 Treatments: Warmline for LTCF/SNF staff: 1-866-268-4322, M-F 8am-5pm, <a href="#">Test to Treat Help Form</a></p>

<b>Immunization Resources</b>
<p><a href="#">California's General Immunization Resources (eziz.org)</a>  <a href="#">RSV Immunization Resources</a>      <a href="#">Flu Vaccination Resources</a>  <a href="#">COVID-19 Vaccination Resources</a>      <a href="#">COVID-19 Treatments</a>  <a href="#">Mpox Vaccination Resources</a></p>

# COVID-19 Vaccine Administration Data

Celeste Romano, CDPH


# COVID-19 Vaccine Administration Summary

as of January 16, 2024

## 95,025,054

Total Doses Administered:


Daily Doses Administered: **Statewide**



## 5,030,496

Total Up-to-Date\* Recipients:

Percent of Population Who Are Up-to-Date




\*Has received a dose of the Updated 2023-2024 vaccine

# Trends in COVID-19 Vaccine Administration

as of January 16, 2024

### Doses Administered by Age Group, Past 4 Weeks



## Most Recent Eligibility Groups

- Updated 2023-2024 vaccine for 6 months and older



# Up-to-Date COVID-19 Vaccination Status

## Race/Ethnicity\* and Age


as of January 16, 2024

### By race and age:

Highest uptake among NHPI, White, and AIAN

Uptake above statewide average in all 65+ race/ethnicity groups

Percent of 65+ Population Who Are Up-to-Date by Age and Race/Ethnicity




\*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination

# Updated 2023-2024 COVID-19 Vaccine Doses

## Providers and Age

as of January 16, 2024

Majority of Pediatric doses are administered by Healthcare providers while Adults receive most of their doses via Pharmacy





# COVID-19 Vaccine Data Summary

as of January 16, 2024

## Key Metrics

<b>95.0 million</b> doses administered	<b>+111K</b> doses administered
<b>12.6%</b> Statewide who are Up-to-Date	<b>5.0 million</b> Up-to-Date recipients
<b>32.0%</b> 65+ population Up-to-Date	<b>2.1 million</b> 65+ Up-to-date recipients

## System Notes

- Public dashboard Up-to-Date status now **includes** the Updated 2023-2024 guidelines
  - Public dashboard updated monthly – LHJ Dashboard updated daily
- Email [cdphvaccinatedatateam@cdph.ca.gov](mailto:cdphvaccinatedatateam@cdph.ca.gov) for questions and comments

# Clinical

Caterina Liu, MD, CDPH

# 2024 Immunization Schedules Now Available

- 2024 pediatric and adult immunization schedules initially released in November 2023
- CDC recently published 2 articles in MMWR\* summarizing updated recommendations.
  - [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger—United States, 2024](#)
  - [Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older—United States, 2024](#)
- Updated schedules include multiple new vaccine recommendations made during 2023, including:
  - RSV immunizations for infants, pregnant people, and older adults
  - PCV20 for children
  - Pentavalent meningococcal vaccine
  - Mpox vaccine
  - Updates to COVID-19, influenza, and polio vaccine recommendations


# California Weekly Report Influenza (Flu), RSV, and Other Respiratory Viruses Week 1: December 31, 2023 – January 6, 2024

## Respiratory Syncytial Virus Surveillance


### RSV Detections from Clinical Sentinel Laboratories

The overall percentage of RSV detections in clinical sentinel laboratories during Week 1 was 9.0% compared to 9.2% during Week 52 ([Figure 12](#)).

**Figure 12. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2018–2024 Season to Date**



## Influenza Activity Levels<sup>+</sup>



Geographic Area	Activity Level
California Statewide	Moderate
Northern Region	Moderate
Bay Area Region	Moderate
Central Region	Moderate
Upper Southern Region	Moderate
Lower Southern Region	Moderate

# Limited Opportunities Remain to Prevent Severe RSV - Order, Use, Reorder Remaining Supplies of Nirsevimab ASAP!





## VFC Program:

- 50 mg and 100 mg doses of nirsevimab available now!

## Private market:

- Check with distributor

### Optimizing RSV Protection for Infants with Limited Supply of Nirsevimab (Beyfortus™)<sup>1</sup> — Update January 2024



**Prenatal Vaccination**  
Administer prenatal RSV vaccine (ABRYOVO™, Pfizer) during 32-36 weeks' gestation, September through January.

- Prenatal vaccination may be the best and only option while RSV immunization for infants (nirsevimab) is in short supply.
- Most infants born to vaccinated birth parents will not need nirsevimab.

**Nirsevimab 50mg** for infants < 5kg and < 8 months without prenatal vaccination<sup>2</sup>

- Administer:
  - Now—infants born prior to October.
  - Within the first week of life—infants born during RSV season.

**Nirsevimab 100mg** for infants ≥ 5kg and < 8 months without prenatal vaccination<sup>2</sup>

- For palivizumab-eligible children, follow [AAP palivizumab recommendations](#) when nirsevimab is not available.

**Nirsevimab 200mg (two 100mg doses)** for children 8 – 19 months

- For palivizumab-eligible children, follow [AAP palivizumab recommendations](#) when nirsevimab is not available.

**RSV Season Is here now!**  
Use and reorder remaining nirsevimab supplies promptly to protect infants and toddlers.

Encourage other preventative measures including:

- [Breastfeeding](#) to decrease the risk of severe RSV and hospitalization among infants
- Recommend everyone around infants are up to date on vaccines including flu, COVID-19, Tdap, and RSV for adults 60 years and older
- Wash hands
- Cover coughs and sneezes
- Clean frequently touched surfaces
- Sick persons should stay away from infants
- Limit number of visitors for infants

**Footnotes:**  
<sup>1</sup>[Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus \(RSV\) during the 2023–2024 Respiratory Virus Season](#)  
<sup>2</sup>Infants <8 months entering their first RSV season should receive immunization if birth parent's prenatal vaccination status is: unvaccinated, unknown, or vaccinated <14 days before birth.

California Department of Public Health, Immunization Branch IMM-1496 (1/24)

# Nirsevimab Resources

**EZIZ**  
A one-stop shop for immunization training and resources.

ENHANCED BY Google

**Home**  
**Vaccine Programs**  
**Vaccine Management**  
**Storage Units**  
**Temperature Monitoring**  
**Training & Webinars**  
**Clinic Resources**  
**Patient Resources**

**RSV**

## RSV Immunization Resources

### General Information for Providers

- RSV Immunization Information (CDC)
- RSV Immunization FAQs
- Updated Guidance for Healthcare Providers on Increased Supply of Nirsevimab to Protect Young Children from Severe Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season
- RSV Trends in the United States (CDC)
- VFC Enrollment Checklist for Birthing/Pediatric Hospitals

### Infants and Children

- Optimizing RSV Protection for Infants with Limited Supply of Nirsevimab Infographic
- Nirsevimab Standing Orders (IAC)
- Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers
- Nirsevimab Guidance (CDC)
- Clinical Guidance to Prevent RSV Disease in Infants Webinar (CDC)
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
- Template Parent Portal and Robocall Messages for Infant RSV Immunization
- ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease (8/15/23)
- Nirsevimab Frequently Asked Questions (AAP)
- Beyfortus (Nirsevimab) Product Insert (FDA)
- CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth (Press Release)

**Contact VFC**  
Phone: (877) 243-8832  
Hours:  
Mon-Thurs, 9AM–4:30PM  
Friday, 9AM–4PM  
Send us an email  
Fax: (877) 329-9832

- ▶ VFC Field Representatives
- ▶ Find VFC providers
- ▶ Sign up for EZIZ emails
- ▶ Frequently Asked Questions

## Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers

Nirsevimab should be given before the start of RSV season (usually October–March). The dosage depends on age, weight, and health condition. View [CDC's RSV page](#) for web version and additional guidance.

### All Infants <8 Months Entering 1st RSV Season

without prenatal vaccination during 32–36 weeks gestational age\*

**If born October–March**  
1 dose in <1 week of birth

**If born April–September**  
1 dose in October/November

Weight <5kg

Nirsevimab  
50mg

OR

Weight ≥5kg

Nirsevimab  
100mg

or as soon as possible during the RSV season

### High-Risk Children 8–19 Months Entering 2nd RSV Season

200mg dose  
before RSV season

Nirsevimab\*\*  
100mg

+

Nirsevimab\*\*  
100mg

or as soon as possible during the RSV season

(Two 100mg syringes, same day, different sites, regardless of weight)

#### High-risk conditions include:

- **Chronic lung disease of prematurity that required medical support** (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) any time during the 6-month period before the start of the RSV season.
- **Cystic fibrosis with either:**
  1. Manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the 1st year if life or abnormalities on chest imaging that persist when stable OR
  2. Weight-for-length <10th percentile
- **Severe immunocompromise**
- **American Indian or Alaskan Native children**



\* In limited situations, an infant may be recommended to receive RSV immunization after prenatal vaccination.

\*\* If nirsevimab is unavailable and the child is eligible to receive palivizumab, then palivizumab should be administered. If < 5 doses of palivizumab are administered and nirsevimab becomes available, the child should receive 1 dose of nirsevimab.

# Trivalent Influenza Vaccine

- Current influenza vaccines are **quadrivalent** and contain 2 influenza A and 2 influenza B strains.
- Given low levels of circulation of B/Yamagata influenza virus, experts have recommended that this strain be removed. This would result in a **trivalent** flu vaccine.
- We may see both trivalent and quadrivalent vaccines during the 2024-2025 influenza season.
  - If both trivalent and quadrivalent vaccines are available, both will be recommended.
- Trivalent and quadrivalent flu vaccines have similar safety profiles and are expected to offer similar protection.
- For more information, see here: [B/Yamagata and Flu Vaccines Summary | CDC](#); [Trivalent versus Quadrivalent Vaccines | CDC](#)


# Therapeutics Billing Update

Edward Salaguinto, PharmD, RPh, CDPH



# Update on Billing for Pharmacists Prescribing Paxlovid

- Business and Professions Code 4052.04 states a pharmacist may furnish COVID-19 oral therapeutics following a positive test for SARS-CoV-2.
- Claims for reimbursement of the professional dispensing fee and ingredient cost must be submitted to Medi-Cal Rx for processing.
- Department of Healthcare Services (DHCS) will reimburse pharmacists for the prescribing (consultation and assessment of need for treatment) of all Paxlovid products.
- Claims must continue to be billed to DHCS as **a medical claim on a CMS-1500 form as a Pharmacist Service.**
  - Use CPT codes 99202 (new patient) and 99212 (existing patient);
  - Eligible claims must have an ICD-10-CM diagnosis code, U07.1 (COVID-19).
- DHCS is extending the temporary allowance to allow billing with these CPT codes from the end of the PHE (May 11, 2023) through September 30, 2024.



**Commercial Paxlovid™ Reimbursement and Update on Billing for Pharmacists Prescribing Paxlovid**  
January 17, 2024

### Background

The Department of Health Care Services (DHCS) is providing the following policy update and billing guidance to pharmacy providers about Paxlovid™ (nirmatrelvir and ritonavir tablets), approved or authorized by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 when independently initiated and furnished by a pharmacist, and about the commercialization of Paxlovid.

### What Pharmacy Providers Need to Know

On May 25, 2023, the FDA approved the use of Paxlovid for the treatment of adults at high risk of progression to severe COVID-19. Paxlovid is still available through an FDA Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19 in non-hospitalized adolescents from 12 to 17 years of age and weighing ≥40 kg.

### Commercialization

On October 13, 2023, Pfizer, the manufacturer of Paxlovid, reached an agreement with the federal government on a timeline to transition Paxlovid from government-managed EUA-Paxlovid distribution to traditional commercial distribution. The commercial transition began on November 1, 2023, as the federal government began to discontinue the distribution of Pfizer's EUA-Paxlovid. Pfizer provided New Drug Application (NDA)-labeled commercial supply to all channels by the end of 2023.

Commercial NDA-labeled Paxlovid is now a covered Medi-Cal Rx benefit for claims with dates of service (DOS) on or after November 1, 2023. Pharmacy providers are encouraged to submit retroactive claims if applicable.

Pharmacy providers will be reimbursed the ingredient cost for commercialized products. The professional dispensing fee will be reimbursed for both NDA and EUA-labeled products. Claims for the dispensing fee and ingredient cost should be billed to Medi-Cal Rx.

Commercial Paxlovid™ Reimbursement and Update on Billing for Pharmacists Prescribing Paxlovid

01/17/2024

# Vaccines for Children (VFC)

Claudia Aguiluz, CDPH

# Continue Ordering Nirsevimab (Beyfortus™)


- Additional allocations of the 100mg and 50mg Beyfortus™ have been received from CDC!
- All VFC providers may order 50mg and 100 mg doses of nirsevimab (Beyfortus™) via supplemental orders
- Current limits and eligibility are subject to change based on supply.

## Respiratory Syncytial Virus Surveillance

### RSV Detections from Clinical Sentinel Laboratories

The overall percentage of RSV detections in clinical sentinel laboratories during Week 52 was 8.6% compared to 9.1% during Week 51 ([Figure 12](#)).

Figure 12. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2018–2024 Season to Date



Note: Data have been shifted so that Week 1 aligns across seasons.

# ABRYSVO™ Available for VFC Ordering this month!

- RSV vaccine ABRYSVO (NDC: 00069-0344-01) is provided through the VFC Program in a 1-pack, 1-dose vial.
  - The minimum order quantity is 1 dose.
- ABRYSVO™ is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration (Sept – January), to prevent RSV lower respiratory tract infection in infants.
- Given the small size of the eligible population and the recommended window for vaccination, the amount of vaccine available within the VFC program is modest. As a result, CDC has allocated doses to each state.

# 12 Days Remain! Submit your 2024 VFC Recertification!

- VFC Recertification Launched: **December 20, 2023**



- Due date: **Wednesday, January 31, 2024**

- Annual 2024 Recertification is completed through MyVFCvaccines

- Annual Recertification and Training **is a federal requirement** to maintain active status in the VFC Program and receive publicly purchased vaccines.

- All public and private providers must recertify yearly

- Even if an LHD clinic is only receiving LHD 317 vaccine for outbreak or SGF vaccine
- Recertification maintains the PIN's active status

# VFC's Provider Satisfaction Survey

[VFC 2024 Provider Satisfaction Survey](#)



A link to complete and submit the VFC Provider Satisfaction Survey will appear after submitting the Recertification form.

Your input is greatly valued and will guide enhancement to our program, educational resources, staff training, and systems

If you haven't had a chance to complete it yet, please complete the survey to finalize your VFC Recertification for 2024.


# VFC 2024-2025 Flu Vaccine Pre-Book

VACCINES FOR CHILDREN (VFC) PROGRAM

## 3 PHASES OF VFC FLU ORDERING



- Launch: **1/19 or early next week**
- VFC Provider Deadline: **February 2, 2024**
- CDC Pre-Book due date: **February 9, 2024**
- Final individual pre-book confirmation emails will be sent to providers after we receive CDC's approval of our CA pre-book.
- Prebooking is the first of three phases of the 2024-2025 VFC flu vaccine order process and will be providers' ONLY chance to provide Flu Product brand preference AND the number of doses needed next season.



# Expected 2024-2025 Flu Vaccine Products

- Actual products that will be available for 2024-2025 VFC Flu Ordering will be dependent upon demand, product availability, and doses approved by the CDC.
- Changes for next season:
  - Fluarix will *not* be on the CDC pediatric contract but will be on the CDC adult contract.
  - FluLaval remains on the CDC pediatric contract but will *not* be on the CDC adult contract.

Age Group	Product	Presentation	Manufacturer
6 months-18 years	<b>Flucelvax</b> <sup>®</sup>	Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*	Seqirus
	<b>FluLaval</b> <sup>®</sup>	Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*	GSK
	<b>Fluzone</b> <sup>®</sup>	Inactivated, No Preservative, 0.5mL single-dose syringe, 10 pack*	Sanofi
2-18 years	<b>FluMist</b> <sup>®</sup>	Live Attenuated, 0.2mL nasal sprayer	AstraZeneca



# Completing your VFC Flu Vaccine Pre-Book for the Upcoming 2024-2025 Influenza Season

## 2024 – 2025 PRE-BOOK PROCESS

**Step 1** - Review your current seasonal influenza data to determine your flu vaccine need for the entire season

**Step 2** - Utilize the [VFC Flu Vaccine Pre-Book Worksheet \(IMM 1454\)](#) to prepare your request prior to accessing the online pre-book form.

**Step 3** – Log-in to your MyVFCvaccines account and click on the “Pre-book Flu Vaccine for 2024-2025” button.

[Pre-book Flu Vaccine for 2024-2025](#)

**Step 4** – Allocate Seasonal Doses by Age Groups Served and Brand Preference

**Step 5** – Submit your 2024-2025 VFC flu vaccine pre-book by **Friday, February 2, 2024.** 

State of California—Health and Human Services Agency California Department of Public Health

VACCINES FOR CHILDREN (VFC) PROGRAM

---

**INFLUENZA VACCINE PRE-BOOK WORKSHEET**

Use this worksheet to prepare for VFC Influenza Vaccine Pre-Book. **DO NOT SUBMIT this worksheet to the VFC Program.**

**STEP 1: Review Your Current Seasonal Influenza Data** to estimate how many VFC doses to order for the ENTIRE upcoming influenza season

- Run flu usage reports (registry/EHR) for the current influenza season.
- Run patient population reports, by age and eligibility.
- Determine how many patients will need more than one dose.

Document the number of VFC eligible patients here:

6 months through 8 years*	9 through 18 years	Total Patients

\* Patients 8 years of age and younger may need 2 doses

**STEP 2: Allocate Seasonal Doses by Age Groups Served and Brand Preference**

- Review available flu vaccine products with practice clinicians and your organization to determine which product(s) to request.
- Based on your patient population, order products licensed for that age group.
- Request ALL doses that will be needed for the upcoming influenza season by brand.

**IMPORTANT:** This is NOT your order for initial flu shipments. Actual products that will be available for the upcoming flu season will be dependent upon demand, product availability, and doses approved by the CDC.

# Flu Vaccine Formulation for the 2024-2025 Season

## Transition to Trivalent Vaccine & Your VFC Pre-book

### Background

- Global influenza surveillance has detected *zero* confirmed influenza B/Yamagata viruses since March 2020.
- Following the October 5, 2023, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting, FDA provided direction for manufacturers to plan for a transition to trivalent flu vaccine.
- As a result, flu vaccines available for the 2024-2025 season may reflect a mixture of trivalent and quadrivalent vaccines.
  - The quadrivalent vaccines contain 2 influenza A strains and 2 influenza B strains.
  - The trivalent vaccine will contain 2 influenza A strains and 1 influenza B strain.

### VFC Pre-books


- The descriptions for flu vaccines in the pre-book do not reference the valency (i.e., trivalent or quadrivalent composition). When CDC confirms the valency after the pre-book, there may be updated NDCs.
- If changes occur, the VFC Program will notify providers of any updates to the NDCs, upon final confirmation of approved pre-books.
- Changes will **not** be made to the brands, presentations, or quantities.

# Expanded Vaccine Recall of Certain Lots of Merck's VAXNEUVANCE™

- In **July 2023**, Merck and the VFC Program had previously sent notices about a **voluntary recall** of certain lots of VAXNEUVANCE™ vaccine.
- Merck is expanding the voluntary recall for VAXNEUVANCE™ due to customer reports of breakage at the syringe flange and/or hub.
- This voluntary partial recall is specific to defects in the syringe and is not related to a quality or safety concern with the vaccine substance manufactured by Merck that is inside the syringe.
- Details about this recall are included in the notification packet that Merck is sending to all providers who received vaccine from one or more of the recalled lots, with specific instructions on returning remaining products.
  - Sedgwick is managing the recall process.
- VFC will be sending out general and targeted communications about the recall to providers.

Confidential

**URGENT: VACCINE RECALL**

 **MERCK**

January 2024  
Event ID: 8681

<b>PRODUCT</b>	Trade Name: Strength:	VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Suspension for Intramuscular Injection (0.5 mL Prefilled Syringe)																							
	NDA Holder:	Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Merck)																							
	NDC Number:	NDC 0006-4329-01 (Syringe) NDC 0006-4329-02 (1X Carton) NDC 0006-4329-03 (10X Carton)																							
	Package Size:	1 Syringe in 1 Carton: W037992 10 Syringes in 1 Carton: W027275, W036242, W039033, X004289, X005583, X011328, X011332, X012044, X011735																							
	Lot Number/Exp Date:	<table border="1"> <thead> <tr> <th>Lot Number</th> <th>Expiration Date</th> </tr> </thead> <tbody> <tr><td>W037992</td><td>10Dec2024</td></tr> <tr><td>W027275</td><td>09Jul2024</td></tr> <tr><td>W036242</td><td>01Oct2024</td></tr> <tr><td>W039033</td><td>01Oct2024</td></tr> <tr><td>X004289</td><td>10Dec2024</td></tr> <tr><td>X005583</td><td>10Dec2024</td></tr> <tr><td>X011328</td><td>01Jan2025</td></tr> <tr><td>X011332</td><td>01Jan2025</td></tr> <tr><td>X012044</td><td>10Jan2025</td></tr> <tr><td>X011735</td><td>10Jan2025</td></tr> </tbody> </table>		Lot Number	Expiration Date	W037992	10Dec2024	W027275	09Jul2024	W036242	01Oct2024	W039033	01Oct2024	X004289	10Dec2024	X005583	10Dec2024	X011328	01Jan2025	X011332	01Jan2025	X012044	10Jan2025	X011735	10Jan2025
Lot Number	Expiration Date																								
W037992	10Dec2024																								
W027275	09Jul2024																								
W036242	01Oct2024																								
W039033	01Oct2024																								
X004289	10Dec2024																								
X005583	10Dec2024																								
X011328	01Jan2025																								
X011332	01Jan2025																								
X012044	10Jan2025																								
X011735	10Jan2025																								
	Distribution:	Distribution by Merck occurred in the United States from 16-Nov-2022 through 28-Jul-2023																							
	Manufactured By:	Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. West Point, PA 19486 U.S.A.																							
<b>REASON</b>	Merck has received reports of breakage at the syringe flange and/or hub that were identified when the syringe was inspected before administration, while the healthcare professional was securing the needle to the syringe, during vaccine administration or during post-administration (e.g., when activating a safety needle). The breakage resulted in a small number of injuries, including laceration and needle puncture. Corrective Action and Preventative Actions (CAPA) have been implemented at the syringe manufacturer to improve processes to help prevent these defects from recurring in future lots and Merck informed Health Care Providers of the glass breakage issue for syringe breakage and provided guidance for handling and administration to further mitigate the risk of injury for the remaining material on the market until post-CAPA material is supplied. Merck has accelerated the supply of post-CAPA material to the U.S. market and has established a stable supply of this																								

Page 1 of 3

# VAXNEUVANCE™ Recall FAQs

- If already administered, are the recalled lots considered a valid dose?
  - Any administered doses of the recalled lots would still be considered valid. Merck's recall is regarding the syringe breakage and not about the quality of the vaccine itself.
- How should providers account for the recalled vaccine?
  - Since the recalled lots should be returned to Merck via Sedgwick, VFC Providers will not be able to return the vaccines as they would other VFC vaccines. Instead, please submit a Wastage Form through your myVFCvaccines account to report these doses as non-usable but cannot be returned to the VFC Program.
- If you received one of the recalled lots, how can you receive more vaccine?
  - You can place a supplemental vaccine order on myVFCvaccines to request more VAXNEUVANCE® vaccine. If your last order was more than 30 days ago, please include your full vaccine inventory for your other available vaccines on your order form to help with vaccine accountability.

# Vaccine Management

Josh Pocus, My Turn, Claudia Aguiluz, myCAvax, and Hannah Shows (Demo)




## New updates for Patients launched on Tuesday, January 9, 2024!

### Release Highlights



#### Patients will be able to view:

- ✓ The 'Single dose' and 'Both doses' options for the question 'Which appointment would you like to schedule for the mpox vaccine?' on the 'Walk-in' page
- ✓ An updated copy for the question 'Which appointment would you like to schedule for the mpox vaccine?'
- ✓ An updated copy on mpox tags on clinic cards on the 'Walk-in' page



# What's New in My Turn? – Release 47 (2 of 2)




## New updates for Clinic Managers and Vaccine Administrators launched on **Tuesday, January 9, 2024!**

### Release Highlights



#### Clinic Managers and Vaccine Administrators will be able to:

- ✓ CQE: Edit previously submitted records when the populated data is incorrect
- ✓ CQE: View all new records uploaded by other users from the same provider location but can only edit the records they have created
- ✓ CQE: View new dropdown options added to the 'Vaccine,' 'Vaccine Family,' 'Manufacturers,' and 'Package Information' fields on the CSV template
- ✓ My Turn Clinic: View new help text added to the 'Date of Birth,' 'Ethnicity,' 'Specify Race / Nationality,' 'Date Administered,' and 'Parent or Guardian's First Name' fields
- ✓ My Turn Clinic: Update and resubmit the appointment with the new products if the product selected during the appointment is an old flu product and was created on or after July 1, 2023





# Introducing California Immunization Registry (CAIR) Quick Entry

The screenshot shows the myCAVax website interface. The top navigation bar includes links for Home, Clinics, Vaccine Inventory, Appointments, Enrollment, IIS Status, and More. The 'More' dropdown menu is open, listing options such as 'Add Walk-In Appointment', 'Bulk Walk-In Upload', 'Manage Users', 'Reports', 'Intraday Report', 'CAIR Quick Entry', 'Upload Records', and 'View/Edit Records'. The 'CAIR Quick Entry' option is highlighted with a red dashed box. Below the navigation bar, there is a 'Welcome to My Turn Clinic' banner and a 'Need Help?' section. The main content area displays three summary cards: 'Appointments by status', 'Completed appointments by vaccine', and 'Completed pediatric appt (<18 yrs)'. The 'View/Edit Records' option in the dropdown menu is also highlighted with a red dashed box.

Since the My Turn Release 46 on **Wednesday, December 20, 2023**, CAIR Quick Entry allows users to submit, view, and edit vaccine administration data for most vaccines to Immunization Information Systems (IIS).


The screenshot shows the 'CAIR Quick Entry View & Edit Records' interface. It features a search form with fields for Location Name, Clinic Name, Status, Submitted From, Submitted To, Vaccine Family, Manufacturer Name, Vaccine, DOB, Last Name, and First Name. Below the search form is a table of records with columns for Record ID, Created Date, IIS Status, Location Name, Clinic Name, Vaccine Family, Manufacturer Name, Vaccine, Date Administered, First Name, Last Name, and Date of Birth. A single record is displayed with the following details: Record ID 66, Created Date Dec 12, 2023, IIS Status, Location Name Sample Locati..., Clinic Name Sample Clinic..., Vaccine Family Hepatitis A, Manufacturer Name GlaxoSmithKline, Vaccine Haurix-Adult, Date Administered Dec 11, 2023, First Name James, Last Name Snow, and Date of Birth Dec 1, 2005. The interface also includes a 'Search' button and a 'Reset' button.



# CAIR Quick Entry and My Turn

With the CAIR Quick Entry feature in My Turn, clinicians gain the ability to:

- **Report Vaccine Administration Data:** CAIR Quick Entry allows clinicians to report vaccine administration data to IIS. Note that a My Turn account is required to use CAIR Quick Entry. Clinicians are not required to manage vaccine appointments in My Turn.
- **Achieve Comprehensive Reporting:** CAIR Quick Entry can be used to report data for all vaccines accepted by CAIR, including flu, mpox, and COVID-19 vaccine.
- **Explore the Streamlined Process with My Turn:** If My Turn is clinicians' preferred platform for managing appointment scheduling, vaccine administration data will continue to be reported to IIS using the usual process.



**Q&A**

# My Turn – Known Issues and Workarounds



## Known Issues

### Date Administered Discrepancy: Backend vs. Clinic Portal

- ✓ We fixed an issue where the Date Administered information on the backend did not match the date presented on the clinic portal.

### Funding Source is Showing Up as 'Unknown' on the CAIR2 Side

- ✓ We have addressed an issue where the vaccines were documented in My Turn with a funding source as 'State General Funding.' However, CAIR2 read the funding source as 'Unknown.'



## Workaround / Next Steps

- ✓ Fixed: **Tuesday, January 9, 2024**

- ✓ Fixed: **Tuesday, January 9, 2024**

- ✓ My Turn accurately transmits 'State General Funding.' However, the term 'Unknown' in the CAIR2 portal was not sourced from My Turn and instead, linked to a particular lot number in the site's existing inventory, and the funding source information was not preserved when the lot inventory reached zero.

# Vaccines for Adults (VFA) / LHD 317 Program Timeline and Next Steps



## October 2023

- Final myCAvax Release until February
- VFA / LHD 317 Ordering in the VFC system
- Development for the VFA / LHD 317 program begins
- Data migration activities begin

## November 2023

- LHD 317 Ordering in the VFC system
- VFA off-cycle for Orders
- Development for the VFA / LHD 317 program continues
- First round of User Acceptance Testing (UAT) for the VFA / LHD 317 program
- Data migration activities continue

## December 2023

- Recertification opens for the VFA / LHD 317 program in the VFC system
- LHD 317 Ordering in the VFC system
- VFA off-cycle for Orders
- Development for the VFA / LHD 317 program continues
- Second round of UAT for the VFA / LHD 317 program
- Data migration activities continue

## January 2024

- Recertification closes for the VFA / LHD 317 program in the VFC system
- VFA / LHD 317 Ordering in the VFC system – closes by the end of January
- Training for CDPH
- Development for the VFA / LHD 317 program continues
- Third round of UAT for the VFA / LHD 317 program
- Data migration activities continue

## February 2024+

- Development for the VFA / LHD 317 program completes
- Final round of UAT for VFA / LHD 317
- Data migration activities complete
- Recertification for the VFA / LHD 317 program in the myCAvax system
- Training for providers
- VFC system shut-down for the VFA / LHD 317 program
- LHD 317 Ordering in the myCAvax system
- VFA Ordering in April in the myCAvax system

# VFA Upcoming Actions for Providers

January 25, 2024

## Vaccine Orders

- Last day to submit vaccine orders and transfers (if applicable) in MyVFCvaccines.

**NOTE:** Ordering will be closed until next VFA quarterly cycle (April 2024).

January 31, 2024

## Account Management

- Complete recertification part 1 in MyVFCvaccines.
- Review and update your site's VFA contact.

## Vaccine Orders

- Submit order corrections if needed.

## Training

- Identified VFA key practice staff should register and attend the training on February 22 and 29, 2024.

By February 9, 2024

**Ensure all VFA program transactions have been recorded in MyVFCvaccines by EOD.**

## Last day in MyVFCvaccines for:

- Recording shipment incidents, temperature excursions, waste and transfers.

February 10 - 19, 2024

## Transition Week

- VFA program data will be migrated to myCAvax.

February 20, 2024

## Go Live

First day in myCAvax for:

- Completing recertification part 2 by verifying clinic information and updating key practice staff managing the adult population
- Completing all required training (lesson details forthcoming)
- Signing the VFA agreement and addendum via DocuSign

## After Submitting Recertification Part 2

In myCAvax, you can:

- View shipping history
- Record shipment incidents, temperature excursions, transfers, and waste
- Return spoiled, expired, or wasted vaccines
- Prepare to order vaccine when the next VFA ordering cycle opens in April 2024

## Support

- Contact the Provider Call Center for support via phone and email when needed.

February 22, 2024

## CDPH Training

- [Register](#) and attend the *VFA 101 Training for Providers* at **11:00 AM PT.**
- **NOTE:** Your identified VFA key practice staff should register for the above training and will receive email in early February regarding training reminders and next steps.

February 29, 2024

## CDPH Training

- [Register](#) and attend the *VFA 102 Training for Providers* training at **11:00 AM PT.**
- **NOTE:** Your identified VFA key practice staff should register for the above training and will receive email in early February regarding training reminders and next steps.

# VFA / LHD 317 Upcoming Training Awareness



With the VFA / LHD 317 programs being released in myCAvax on **Tuesday, February 20, 2024**, CDPH will begin system training for LHDs and providers.

Identified VFA key practice staff should attend 2 trainings:

- [VFA 101 Training for Providers](#) on **Thursday, February 22, 2024**, at **11:00 am PST**
- [VFA 102 Training for Providers](#) on **Thursday, February 29, 2024**, at **11:00 am PST**

Register on Zoom for both trainings.

# VFA / LHD 317 Recertification Deadline / Reminder



With the VFA / LHD 317 program being released in myCAvax on **Tuesday, February 20, 2024**, all the VFA / LHD 317 providers must complete the recertification process.

During the VFC recertification process, all the VFA and LHDs providers must:

- Enter / update clinic information in MyVFCvaccines by **Wednesday, January 31, 2024**; this information will be migrated and pre-populated in the myCAvax recertification form
- Review and update their site's VFA contact on MyVFCvaccines. This will be the only key practice staff information migrated to myCAvax. The VFA contact will be designated as the Primary Vaccine Coordinator in myCAvax.

After VFA / LHD 317 release in myCAvax on **Tuesday, February 20, 2024**:

- Complete the information verification process in myCAvax in **February 2024**
- Update the key practice staff managing the adult population on myCAvax
- Complete all required EZIZ training (Lesson details forthcoming)

The Provider of Record must review, acknowledge, and sign the VFA / LHD 317 Agreement and Addendum on myCAvax to complete the recertification process.

# Bridge Access Program (BAP): Vaccine Allocations Cadence Update



Allocations of BAP COVID-19 vaccine products are refreshed on a biweekly cadence. CDPH receives allocations mid-week and distributes inventory to the LHDs within a few business days.

The most recent CDC allocation refresh was received **Wednesday, January 17, 2024**. Doses were added to LHD allocations the same day.



# Reminder: New Refrigerated Pfizer COVID-19 Vaccine for 12 Years+



The previous Pfizer 12y+ vaccine allocations have been replaced with Pfizer's new refrigerated 12y+ vaccine (NDC 00069-2377-10), a new presentation in a carton of 10 manufacturer-filled syringes (MFS).

Providers who have the original Pfizer 12y+ vaccine on hand can and should continue to use this product until it is consumed, expired, or has been stored at 2–8 °C for longer than the allowable 10 weeks.

**Important:** There are no temperature monitors being shipped with this product. Shipments maintain temperatures for 84 hours. **Please check the shipment's date (on the shipment label outside)** to ensure it is received within this timeframe.

# McKesson COVID-19 Vaccine Shipping Update



Beginning this week, McKesson will temporarily be using one of the two warm temperature monitors for vaccine shipment. Coolers may contain the familiar 3M monitor or the new monitor, SpotSee (WarmMark).

This temporary change in temperature monitors is expected to be in place until **Thursday, February 1, 2024**, when a new and improved temperature monitor will be used for refrigerated shipments. See [Supplemental Resource on Temporary Loggers](#) provided by McKesson for additional support.

Both the 3M and SpotSee monitors are one-time use only and should be disposed of once the vaccine has been properly stored.

Please follow the same process for checking any temperature excursions and follow the directions on the information card specific to the monitor received.

**MCKESSON**  
Empowering Healthcare

### How to Read the WarmMark® Temperature Indicator

As soon as you receive this shipment, remove the WarmMark® Temperature Indicator and check the Index. Please note that all pictures below are examples only. Please read the monitor on the other side of this card.

**For all vaccines excluding MMR:**

- If the Index color is MODERATE, store the vaccines as instructed and begin use.
- If the Index color is PROLONGED, store the vaccines as instructed and call 877-TEMP123 (877-836-7123) or your state / local immunization program right away for further instruction before using.

**For MMR vaccines only:**

- If the Index color is BRIEF, store the vaccines as instructed and begin use.
- If the Index color is MODERATE or PROLONGED, store the vaccines as instructed and call 877-TEMP123 (877-836-7123) or your state / local immunization program right away for further instruction before using.

**WarmMark® Time Temperature Indicator decision table:**

Indicator Color	Vaccine Type	
	Vaccines (excluding MMR)	MMR
BRIEF	Ready for Use	
MODERATE	Ready for Use	Call 877-TEMP123 (877-836-7123) or your state / local immunization program <u>right away</u>
PROLONGED	Call 877-TEMP123 (877-836-7123) or your state / local immunization program <u>right away</u>	

Call 877-TEMP123 (877-836-7123) or your state / local immunization program right away if you have questions or concerns when reading the temperature indicator or if you see damage to the package.

# January BAP Holiday Shipping Cadence

## January Holiday Ordering & Distribution Cadence Calendar

California BAP COVID-19 Vaccination Program (Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
January 01	02	03	04	05
Holiday Hold – No Vaccine Deliveries	Provider Order (submit by 3PM)	LHD Approval by 12PM		
		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			
08	09	10	11	12
Provider Order (submit by 5PM)		LHD Approval by 12PM		
		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			
15	16	17	18	19
Provider Order (submit by 3PM)		LHD Approval by 12PM		
Holiday Hold – No Vaccine Deliveries		CDPH Transmits to CDC		
	Estimated Delivery – McKesson (Moderna/Novavax) & Pfizer			



- Delivery windows are dependent on provider's days/hours of operation. Shipments will be sent the following week of order approval and processing. [\*\* Adjusted Delivery date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

# January SGF Holiday Shipping Cadence

## January Holiday Ordering & Distribution Cadence Calendar




California SGF Flu Vaccination Program (Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
January 01	02	03	04	05
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
Holiday Hold – No Vaccine Deliveries	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)
08	09	10	11	12
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)
15	16	17	18	19
	LHD Approval by 12PM			LHD Approval by 12PM
	CDPH Transmits to CDC			CDPH Transmits to CDC
Holiday Hold – No Vaccine Deliveries	Flu Vaccine Delivery – McKesson Direct Ship			
		Provider Order (submit by 5PM)		Provider Order (submit by 5PM)



- Delivery windows are dependent on provider's days/hours of operation. Shipments will be sent the following week of order approval and processing.[\*\* Adjusted Delivery date due to Holiday]
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

# Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

# myCAvax – Known Issues and Workarounds



## Known Issues

### Transfer and Order Related List Views Tied Together

- ✓ We will be correcting a visibility issue in which Sending Transfers are only visible on a Vaccine Order's related list views when looking at an Account or Program Location. While Receiving Transfers have their own unique related list view, Sending Transfers should also have their own unique related list view.

### Some Sending Transfers Missing from Program Related List Views

- ✓ We will be correcting an issue in which some Sending Transfers are not showing in their respective Program Location's related list views but are still visible from their Account's related list views – for now, the Account should be taken as the source of truth if you notice a mismatch.



## Workaround / Next Steps

- ✓ Estimated Fix: **February 2024**

- ✓ Estimated Fix: **February 2024**

# Resources and Q&A

Leslie Amani and CDPH SMEs



ENHANCED BY Google

**A one-stop shop for immunization training and resources.**

**Home**

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

---

**Contact VFC**

Phone: (877) 243-8832  
Hours: Mon-Thurs, 9AM-4:30PM  
Friday, 9AM-4PM  
Send us an email  
Fax: (877) 329-9832

- ▶ VFC Field Representatives
- ▶ Find VFC providers
- ▶ Sign up for EZIZ emails
- ▶ Frequently Asked Questions

**California's Vaccine Programs**

 <b>VFC</b> <small>California Vaccines for Children Program</small>	 <b>VFA</b> <small>California Vaccines for Adults Program</small>	 <b>BAP</b> <small>California Bridge Access Program</small>	 <b>317</b> <small>Local Health Departments</small>
---	---	---	---

**Ordering & Vaccine Management**

**Storage Requirements**

<ul style="list-style-type: none"> <li>• MyVFCvaccines (for VFC and VFA)</li> <li>• MyCAvax (for BAP and 317)</li> </ul>	<ul style="list-style-type: none"> <li>• Vaccine Storage Units</li> <li>• Digital Data Loggers</li> </ul>
--	---

**Alerts!**

**2023-24 COVID-19 Vaccine**

- [COVID-19 Vaccine Resources: For Providers | For Patients](#)
- [Vaccine Ordering and Manufacturer Info](#)

**Protect your patients against RSV!**

- [RSV Immunization FAQs](#)
- [Resources for Providers and Patients](#)

**Holiday Ordering & Distribution Cadence Calendars**

- [VFC Program](#)
- [CA BAP COVID-19 Vaccine Program](#)
- [CA SGF Flu Vaccination Program](#)

VFC Memos

Vaccine Order Status

From CDPH

**Hot Topics**

**Weekly CDPH Immunization Updates for Providers**

- [Immunization Registry Requirements](#)
- [COVID-19 Vaccine Resources](#)

**Popular Resources**

- ▶ [For Patients and Staff](#)
- ▶ [Flu](#)
- ▶ [Mpox](#)
- ▶ [Pertussis](#)
- ▶ [Schedules & Recommendations](#)
- ▶ [VFC Vaccine Fact Sheets](#)
- ▶ [For Pharmacies](#)

**CDPH Applications**

- ▶ [My Turn](#) (COVID/Flu Vaccine Administration System)
- ▶ [CAIR](#) (California Immunization Registry)
- ▶ [My DVR](#) (Digital Vaccine Records)
- ▶ [CAIR-ME](#) (Medical Exemptions from Immunizations for School and Child Care)

**COVID-19 Vaccine Resources**

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines.

**Jump To Topic:**

- [Vaccine Information](#)
- [Clinical Resources](#)
- [Vaccine Administration](#)
- [Communicating with Patients](#)
- [Archived Communications](#)

**Vaccine Information**

- [Required Vaccine Product Training](#) (CDC)
- [COVID-19 Vaccine Fact Sheets](#) (CDPH)
- [COVID-19 Vaccine Product Guide](#)
- [COVID-19 Vaccine Timing Guide | Spanish](#)
- [Vaccine Program Eligibility Guidelines: VFC, VFA, BAP](#) (for Community Health Centers)
- [Vaccine Ordering & Manufacturer Info](#) (private and public vaccines)
- [COVID-19 Provider FAQs](#) (Updated 12/14)
- [COVID-19 Vaccine Product Information Guide](#) (CDC, not yet updated for 2023)
- [Receiving & Storage Vaccine Shipments](#)

**Pediatric Vaccine Resources**

- [COVID-19 is a Childhood Illness](#) (CDPH)
- [6 Things to Know about COVID-19 Vaccination for Children](#) (CDC)
- [Equity in Childhood COVID-19 Vaccination](#) (CDC)

**Vaccine Information Statements (VISs)**

Currently, providers are required by law to provide EUA fact sheets to vaccine recipients or their caregivers for all uses of Novavax and when Moderna or Pfizer vaccines are given to children 6 months through 11 years of age. For recipients who are 12 or older receiving Pfizer or Moderna vaccine, a provider may use the COVID-19 Vaccine Information Statement (VIS). See [CDC Vaccine Information Statements](#).

**Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)**

- [Pfizer at a Glance](#) (CDC)
- [Pfizer Storage and BUD Label](#)
- [Approval of Comirnaty for 12Y+: Provider Letter | Package Insert | COMIRNATY](#) (FDA)



# COVID-19 Vaccine and Therapeutics FAQs

## Answers to providers' COVID-19 vaccine and therapeutics questions!

Updated Thursday, January 11, 2024

 Updated **Q: *Where can I find information about COVID-19 vaccination and pregnancy?***

A: COVID-19 vaccination [is recommended](#) for people who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. For patient resources, please refer to [CDPH Pregnancy and Immunizations Toolkit](#).

 Updated **Q: *Is there a refrigerated presentation of COVID-19 vaccine?***

A: Yes. There is a new refrigerated Pfizer 12y+ COVID-19 vaccine. This new presentation comes as single-dose pre-filled syringes and must be stored between 2°C - 8°C (36°F and 46°F). For more information and resources, please refer to this [CDPH communication](#), the updated [COVID-19 Vaccine Adolescent/Adult \(12Y+\) fact sheet](#), and the updated [COVID-19 Vaccine Product Guide](#).

COVID-19 Vaccine and Therapeutics FAQs v.138\_01.11.24 1

### COVID-19 Vaccine and Therapeutics FAQs

For providers administering COVID-19 vaccine, and treating COVID-19. Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

<a href="#">New and Updated FAQs</a>	2
<a href="#">COVID-19 Vaccine Access</a>	2
<a href="#">Bridge Access Program (BAP)</a>	4
<a href="#">Vaccine Administration</a>	8
<a href="#">Vaccine Storage &amp; Handling</a>	10
<a href="#">Reporting</a>	11
<a href="#">Therapeutics</a>	13
<a href="#">Communication Resources</a>	14

# Provider Operations Manual California Bridge Access Program

## Special Note for Providers

You played a critical role in helping to end the COVID-19 pandemic.

For patients, you are one of the most trusted sources of information when it comes to vaccines. Patients may have questions and concerns about COVID-19 vaccines. You can help them understand the importance of vaccination, provide your strong recommendation, and build confidence in vaccines.

Strong vaccine confidence leads to more people getting vaccinated, which leads to fewer COVID-19 illnesses, hospitalizations, and deaths.

Thank you for the efforts you and your practice staff are making to keep California healthy.



California Bridge Access Program  
**Provider Operations Manual**

no-cost COVID-19 vaccines *thank you* for uninsured & underinsured adults

**Click to Navigate**  
Table of Contents

**Startup Guide**

**Ordering Vaccines**  
1 About vaccine orders  
Vaccine products  
Submitting vaccine order requests  
Minimizing shipment delays  
When to expect vaccines

**Receiving & Storing Vaccine Shipments**  
2 About receiving shipments  
Moderna  
Novavax  
Pfizer-BioNTech  
Reporting shipment incidents

**Routine Tasks & Reporting**  
3 Recurring tasks & frequency  
Reporting requirements  
Reporting temperature excursions  
Reporting expiration & beyond-use dates  
Wastage & missed opportunities  
Reporting & return of nonviable doses  
Transporting vaccines  
Transferring vaccine

**Managing Vaccine Inventory**  
4 Inventory management checklist  
Monitoring temperatures  
Reporting temperature excursions  
Vaccine preparation & administration  
Responding to administration errors  
Billing & Reimbursement

**Appendices**  
Important contacts

**Infrequent Tasks**  
Introduce new vaccines, change staff or contacts, set up new storage unit, and data logger

**Patient Visit**  
5 Patient visit checklist  
Eligibility Screening & Documentation  
How to Screen & Document Eligibility  
Vaccine preparation & administration  
Responding to administration errors  
Billing & Reimbursement

CDPH | BAP California Bridge Access Program

# Vaccine Support


## Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: [myCAvax.hd@cdph.ca.gov](mailto:myCAvax.hd@cdph.ca.gov)
- For My Turn Clinic Help Desk inquiries: [MyTurn.Clinic.HD@cdph.ca.gov](mailto:MyTurn.Clinic.HD@cdph.ca.gov)
- For all other inquiries: [providercallcenter@cdph.ca.gov](mailto:providercallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

## myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



# COVID-19 Therapeutics Resources

## Type of Support


## Description

Updated 11.27.23



### Clinical Guidance

For general Therapeutics questions, please email: [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
COVID-19 Treatment Warmline for SNF and LTCF staff: 1.866.268.4322 M-F 8am-5pm



### General Information


[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)  
[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)  
[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)  
[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



### Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



### LHJ Therapeutics SharePoint

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email [JEOCuser54@cdph.ca.gov](mailto:JEOCuser54@cdph.ca.gov))

- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPOP Account Verification & Reporting](#) information




### Questions

For general CDPH Therapeutics questions, please email [COVIDRxProviders@cdph.ca.gov](mailto:COVIDRxProviders@cdph.ca.gov)  
For ordering, program inquiries, signing up new HPOP Accounts: please e-mail [CDPHTherapeutics@cdph.ca.gov](mailto:CDPHTherapeutics@cdph.ca.gov)

# Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, "Chat"



# Upcoming CDPH Webinar Opportunities

## CDPH Immunization Updates for Providers

**Next session: Friday, January 26, 2024**

**9AM – 10:30AM**

